2958-87-4

Basic information

• Product Name: 2,3,6-TRICHLOROQUINOXALINE
• Synonyms: 2,3,6-TRICHLOROQUINOXALINE;Quinoxaline, 2,3,6-trichloro.;2,3,6-TRICHLOROQUINOXALINE 98%;2,3,6-Trichloroquinoxaline ,98%;2,3,6-Trichloropyrimidine;NSC 203052;6-chloro-2,3-dichloroquinoxaline
• CAS NO: 2958-87-4
• Molecular Formula: C₈H₃Cl₃N₂
• Molecular Weight: 233.48
• EINECS: 220-987-3
• Mol File: 2958-87-4.mol
• Article Data: 19

Chemical Properties

• Melting Point: 143-148 °C
• Boiling Point: 373.7°C (rough estimate)
• Flash Point: 160°C
• Appearance: /
• Density: 1.600
• Vapor Pressure: 0.00281mmHg at 25°C
• Refractive Index: 1.6000 (estimate)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2,3,6-TRICHLOROQUINOXALINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3,6-TRICHLOROQUINOXALINE(2958-87-4)
• EPA Substance Registry System: 2,3,6-TRICHLOROQUINOXALINE(2958-87-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 37/39-26-24/25
• Hazardous Substances Data: 2958-87-4(Hazardous Substances Data)

Usage

Chemical Properties

Pink-brown granular powder

InChI:InChI=1/C8H3Cl3N2/c9-4-1-2-5-6(3-4)13-8(11)7(10)12-5/h1-3H

Upstream product

• 6639-79-8 6-chloroquinoxaline-2,3(1H,4H)-dione 
• 5448-43-1 6-chloroquinoxaline 
• 6639-79-8 2,3-dihydroxy-6-chloroquinoxaline 
• 552-32-9 o-nitroacetanilide 
• 68-12-2 N,N-dimethyl-formamide 
• 89-63-4 4-Chloro-2-nitroaniline 
• 95-83-0 4-Chloro-1,2-phenylenediamine 

Downstream Products

• 143702-81-2 7-Chloro-2-phenyl-4a,5,10,11-tetraaza-benzo[b]fluorene 
• 52312-40-0 6-Chlor-2,3-diamino-chinoxalin 
• 1374748-82-9 2-(3-(4-bromo-2-fluorophenoxy)-7-chloro-2-oxoquinoxalin-1(2H)-yl)acetic acid 
• 1374748-81-8 2-(3-(4-bromophenoxy)-7-chloro-2-oxoquinoxalin-1(2H)-yl)acetic acid 
• 1374748-80-7 2-(7-chloro-3-(4-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetic acid 
• 1374748-65-8 methyl 2-(3-(4-bromo-2-fluorophenoxy)-6-chloro-2-oxoquinoxalin-1(2H)-yl)acetate 
• 1374748-64-7 methyl 2-(3-(4-bromophenoxy)-6-chloro-2-oxoquinoxalin-1(2H)-yl)acetate 
• 1374748-63-6 methyl 2-(6-chloro-3-(4-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetate 
• 1374748-56-7 methyl 2-(3-(4-bromo-2-fluorophenoxy)-7-chloro-2-oxoquinoxalin-1(2H)-yl)acetate 
• 1374748-55-6 methyl 2-(3-(4-bromophenoxy)-7-chloro-2-oxoquinoxalin-1(2H)-yl)acetate 
• 1374748-54-5 methyl 2-(7-chloro-3-(4-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetate 
• 91896-68-3 (8-Chloro-1-ethyl-[1,2,4]triazolo[4,3-a]quinoxalin-4-yl)-((S)-1-methyl-2-phenyl-ethyl)-amine 
• 91925-59-6 (8-Chloro-1-ethyl-[1,2,4]triazolo[4,3-a]quinoxalin-4-yl)-((R)-1-methyl-2-phenyl-ethyl)-amine 
• 91896-21-8 CP 66278 

Relevant articles and documents

Novel molecular targeting anti-tumor aza-steroid derivative based on lipid toxicity and preparation and application thereof

The invention provides a novel molecular targeting anti-tumor aza-steroid derivative based on lipid toxicity and a preparation method and application thereof, and belongs to the field of chemical medicines. The derivative is a compound as shown in a formula I, or a salt thereof, or a stereoisomer thereof. The compound is low in toxicity or basically non-toxic to normal cells, has an obvious inhibition effect to tumor cell lines, particularly has good lipid toxicity selectivity to tumor cells such as liver cancer, lung cancer and the like in vivo, and has an obvious inhibition effect; meanwhile, the compound can effectively activate SREBP1 and PPAR gamma, inhibit lipid transport MTTP, cause lipid aggregation in tumor cells and cause lipid toxicity of the tumor cells. The compound can be used for treating liver cancer, lung cancer and the like in a molecular targeting manner, is low in toxicity or even non-toxic, and has a good application prospect.

Method for preparing 2,3-dichloro-quinoxaline derivative through one-pot procedure

The invention belongs to the field of drug synthesis, and specifically relates to a new method for preparing 2,3-dichloro-quinoxaline derivative through one-pot procedure. According to the method, cheap o-phenylenediamine and oxalic acid are adopted as raw materials, and the cheap and easily available and environmentally friendly silica gel or methanesulfonic acid is adopted as a catalyst while steps of intermediate separation and purification are omitted; the method has the advantages of easiness in operation, low cost, mild reaction conditions and environmental friendliness and promotes industrial mass production.

HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE

The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.